Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published on September 27, 2023
New York, NY – September 27, 2023 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego (CA).
Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.
Title: TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion Synergize to Optimize Potency of MUC1-CAR T-cells in Preclinical Targeting of Triple-Negative Breast Cancer.
Poster Number: 254
Presenter: Laurent Poirot, Ph.D., SVP Immunology, Cellectis.
Date/Time: Poster will be on display Saturday, November 4th, 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.
Full text of the abstract will be made public on October 31, 2023 at 9:00 a.m. EDT on the SITC website and in a Journal for ImmunoTherapy of Cancer (JITC) supplement published on Oct. 31st, 2023 at 6 a.m. PDT/9 a.m. EDT.